|
|
News Breaks | | | | November 27, 2012 | | 06:43 EDT |  | CLSN, KCG | Stocks with implied volatility movement; CLSN KCG
Stocks with implied volatility movement; Celsion (CLSN), Knight Capital (KCG) according to iVolatility. | |
|
News For CLSN;KCG From The Last 14 Days Check below for free stories on CLSN;KCG the last two weeks. |
|
|
| June 18, 2013 | | 09:56 EDT |  | KCG | Knight Capital to host special shareholder meeting
Special Shareholder Meeting to consider and vote on the merger with GETCO Holding is being held in Jersey City, New Jersey on June 25 at 1 pm. | | | June 12, 2013 | | 15:44 EDT |  | CLSN | Celsion issues statement regarding Seeking Alpha post
 Subscribe for More Information | | | June 11, 2013 | | 18:50 EDT | | CLSN | On The Fly: After Hours Movers
UP AFTER EARNINGS: Ulta Salon (ULTA), up 9.5%. ALSO HIGHER: Rambus (RMBS), up 8.2% after announcing a patent license agreement that will pay the company $12M per quarter for the next five years. LOWER: Celsion (CLSN), down 22.6% after a Seeking Alpha contributor said the company's Phase III ThermoDox trial was a "total disaster" and that the stock could have 50% downside... Yum! Brands (YUM), down 1.7% after saying it sees Q2 China division same-store sales down 20%... First Solar (FSLR), down 7.1% after filing to sell 8.5M shares of common stock... Icahn Enterprises (IEP), down 5.1% after announcing an offering of depositary units representing limited partner interests. | | | 17:05 EDT | | CLSN | Celsion slips after Seeking Alpha contributor sees 50% downside
Shares of Celsion (CLSN) are trading lower after-hours after a Seeking Alpha contributor said the company's Phase III ThermoDox HEAT trial was a "total failure." WHAT'S NEW: According to a post from a Seeking Alpha contributor, Celsion's Phase III ThermoDox HEAT trial was a "total failure." The author said they spoke to "key opinion leaders as well as doctors" that participated in Celsion's Phase III study. The article said that the failure of this trial gives Celsion "no chance" of getting regulatory approval, giving Celsion a worthless asset in ThermoDox. The contributor, who discloses holding a short position in Celsion's shares, puts a 73c price target on the stock, or more than 50% downside from today's closing price of $1.59 per share. PRICE ACTION: Shares of Celsion are down about 80% year-to-date, but have gained over 60% in the last month, closing as high as $1.96 per share on May 30. In after-hours trading, Celsion is down about 29c, or 18.24%, to $1.30 per share. Reference Link | |
|
|
|
|
|
|
